Gastrointestinal amyloidosis: A focused review

doi:10.4253/wjge.v13.i1.1

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9643)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-3) series.

Item

Count

PDF

642

WORD

249

HTML

5463

Tables (1-3)

340

Sum=6694

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

370

Download

862

Sum=1232

Publishing Process of This Article

Item

Count

Browse

636

Download

1081

Sum=1717

Jan 16, 2021 (publication date) through Jan 18, 2025

Times Cited of This Article

Times Cited (39)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Endoscopy

ISSN

1948-5190

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastrointest Endosc. Jan 16, 2021; 13(1): 1-12
Published online Jan 16, 2021. doi: 10.4253/wjge.v13.i1.1

Table 3 Management of gastrointestinal amyloidosis based on the amyloid protein

Gastrointestinal amyloidosis	AL amyloidosis	AA amyloidosis	Hereditary amyloidosis	Dialysis-related amyloidosis
Treatment strategy	Systemic: Eligible: Autologous stem cell transplantation (ASCT) for plasma cell dyscrasias. Non-eligible: No standard protocol; combination of Bortezomib, Melphalan and Dexamethasone has shown improved survival. Localized: Observation or localized surgical excision	Chronic inflammatory conditions: Biologics (anti-TNF antibodies, humanized anti-IL6 receptor antibody) and immunosuppressants. Familial mediterranean fever: Colchicine.	Liver production of transthyretin: Orthotopic liver transplantation (OLT). Disease modifying therapy: Transthyretin stabilizers (Tafamidis and Diflunisal), Doxycycline, Patisiran and Inotersen may be used on case-to-case basis	Prevention: Removal of plasmatic β2-microglobulin (Aβ₂M) through hemodialysis or peritoneal dialysis. Early renal transplant

Citation: Dahiya DS, Kichloo A, Singh J, Albosta M, Wani F. Gastrointestinal amyloidosis: A focused review. World J Gastrointest Endosc 2021; 13(1): 1-12
URL: https://www.wjgnet.com/1948-5190/full/v13/i1/1.htm
DOI: https://dx.doi.org/10.4253/wjge.v13.i1.1